参芪扶正注射液联合姑息性化疗对晚期结直肠癌疗效的临床观察

目的观察晚期结直肠癌姑息性化疗中联合应用参芪扶正注射液的疗效遥方法将118 例晚期结直肠癌患者随机分为 治疗组(参芪扶正注射液联合姑息性化疗)61 例和对照组(单纯姑息性化疗组)57 例,对比观察两组患者3 周期姑息性化疗后的 总体有效率尧化疗不良反应和生活质量改善情况遥结果治疗组总有效率77.05%,对照组56.14%,治疗组总有效率明显优于对 照组,两组间差异显著( 约0.05)曰治疗组患者胃肠道反应尧骨髓抑制等不良反应发生率均显著低于对照组( 约0.05)曰患者生存质 量改善情况治疗组（68.85%）优于对照组（49.12%）,两组差异有统计学意义( 约0.05)遥结论晚期结直肠癌患者姑息性化疗联合 应用参芪扶正注射液,能够取得较好疗效,同时减轻化疗不良反应尧改善生活质量     

不同生物制剂治疗类风湿性关节炎有效性及安全性的网状Meta分析

目的:临床中治疗类风湿性关节炎的生物制剂多种多样,其疗效及安全性差异尚不明确,文章旨在比较不同生物制剂治疗类风湿性关节炎的有效性及安全性的差异。方法:检索中国知网、维普、万方、中国生物医学文献系统数据库、PubMed、Cochrane图书馆、Web of Science和Embase数据库的文献,收集各数据库建库至2022-10-01符合要求的关于类风湿性关节炎生物制剂治疗的随机对照试验。运用EndNote软件筛选文献,RevMan 5.3软件对纳入的文献进行质量评价;采用Stata 14.2软件对ACR20(美国风湿学会20%缓解率)、ACR50(美国风湿学会50%缓解率)、ACR70(美国风湿学会70%缓解率)、红细胞沉降率及不良反应指标进行直接Meta分析及网状Meta分析。结果:共纳入符合要求的文献39篇,5篇低风险文献,4篇含高风险文献,剩余30篇含有风险未知偏倚,共13种治疗措施。网状Meta分析结果:(1)在ACR20方面,英夫利昔单抗联合甲氨蝶呤(OR=5.54,95%CI:1.33-23.01,P <0.05)、阿巴西普+甲氨蝶呤片(OR=3.21,95%CI:...     

基于系统评价的复方斑蝥胶囊治疗结直肠癌的疗效及经济性评价

目的:基于文献数据,系统评价复方斑蝥胶囊治疗结直肠癌的的有效性和经济性.方法:检索2010年1月至2021年4月各中英文数据库,采用RevMan5.3软件对符合纳入排除标准的文献数据进行Meta分析,结合各治疗方案的成本进行药物经济学评价.结果:共纳入9个RCT,共860例结直肠癌癌患者.有效性分析结果显示,加用复方斑蝥胶囊组治疗结直肠癌的效果优于对照组.药物经济学评价结果显示,与对照组相比,加用复方斑蝥胶囊组治疗结直肠癌的增量成本效果比为67.2.结论:与常规化疗相比,复方斑蝥胶囊在结直肠癌的治疗中,有效性更好,且具有一定的经济性.     

贝伐单抗联合化学药物治疗耐药晚期非小细胞肺癌

目的：探讨贝伐单抗联合化学药物治疗耐药晚期非小细胞肺癌（non—smallcelllung ca11cer,NSCLC）的疗效及安全性。方法：对2011年1月至2012年9月收治的9例耐药晚期NSCLC患者给予贝伐单抗联合化疗治疗,其中多西他赛联合贝伐单抗3例、培美曲塞二钠联合贝伐单抗5例、紫杉醇联合贝伐单抗1例。每例患者均完成2个周期以上治疗,观察其近期疗效及安全性。结果：9例患者中,3例部分缓解。无进展生存期2～12个月,总生存期4～16个月。主要不良反应有骨髓抑制、下肢静脉血栓、充血性心力衰竭、血压升高、消化道反应以及脱发。结论：贝伐单抗联合化疗治疗耐药晚期NSCLC取得较好疗效,毒性可以耐受。     

曲妥珠单抗联合含多柔比星脂质体治疗HER-2阳性晚期乳腺癌临床疗效观察

目的:观察曲妥珠单抗联合含多柔比星脂质体治疗人类表皮生长因子受体2(Human epidermal growth factor receptor-2,HER-2)阳性晚期乳腺癌临床疗效.方法:选取2018年5月～2020年9月我院收治的HER-2阳性晚期乳腺癌患者80例,根据治疗方式不同分为基础组40例(多柔比星脂质体治疗)和联合组40例(曲妥珠单抗+多柔比星脂质体治疗).对比两组的疗效及肿瘤标志物血清水平.结果:联合组总有效率高于基础组、肿瘤标志物血清水平改善优于基础组(P<0.05).结论:曲妥珠单抗联合含多柔比星脂质体治疗HER-2阳性晚期乳腺癌临床疗效显著,不良反应发生情况少具有使用价值.     

帕尼单抗在治疗转移性结直肠癌中的应用

结直肠癌是癌相关性死亡的第三大死因,转移性结直肠癌患者生存率明显下降,且不少患者对化疗产生耐药。帕尼单抗是第一个全人源单克隆治疗性抗体,选择性地与肿瘤细胞表面表皮生长因子受体特异性结合而发挥抗瘤效果,临床试验研究结果显示帕尼单抗对化疗耐药的转移性结直肠癌具有较好的疗效和安全性,在放射免疫显像及放射免疫治疗中也具有较好的应用前景。     

克癌新汤剂联合化疗治疗晚期结直肠癌疗效观察

目的 观察克癌新汤剂联合FOLFOX4方案治疗晚期结直肠癌的疗效.方法 58例患者随机分为克癌新汤剂组32例和对照组26例,两组均应用FOLFOX4方案化疗,克癌新汤剂组同时加用克癌新汤剂.结果 克癌新汤剂组有效率为68.75%,对照组为46.15% (P < 0.05);克癌新汤剂组体重增加、Kamofsky评分提高均高于对照组,且能改善化疗后机体的免疫功能(P < 0.05);克癌新汤剂组毒副反应明显低于对照组(P < 0.05).结论 克癌新汤剂联合FOLFOX4方案对晚期结直肠癌患者具有明显的增效减毒作用.     

贝伐单抗联合TP方案治疗晚期HER2阴性乳腺癌的临床疗效及对患者相关细胞因子水平的影响

目的 探讨贝伐单抗联合紫杉醇与顺铂联合化疗方案(TP)治疗晚期乳腺癌的临床疗效及对患者相关细胞因子水平的影响.方法 入选2015年3月至2017年3月间于我院治疗的晚期乳腺癌患者60例,随机分成对照组(n=30)和观察组(n =30).对照组患者给予TP方案治疗,观察组患者在TP方案化疗的基础加用贝伐单抗治疗.两组均以3周为一疗程,连续治疗两个疗程后根据改良版实体瘤疗效评价标准(mRCIST)评价疗效,观察并记录治疗前后疾病相关因子水平变化情况及治疗期间的不良反应发生情况.结果 观察组患者治疗后的临床收益率(CBR)显著优于对照组(P＜0.05);治疗后两组患者血管内皮生长因子(VEGF)、白细胞介素-4(IL-4)、白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)水平均明显改善,且观察组显著优于对照组(P＜0.05);治疗过程中两组患者不良反应发生率比较差异无统计学意义(P＞0.05).结论 贝伐单抗联合TP方案治疗晚期乳腺癌的疗效显著,能够有效改善相关细胞因子水平,且安全可靠,值得临床推广.     

利妥昔单抗辅助化疗治疗弥漫大B细胞淋巴瘤临床疗效分析

目的:分析利妥昔单抗辅助化疗治疗弥漫大B细胞淋巴瘤临床疗效.方法:回顾性分析本院自2020年3月-2022年3月期间收治的81例弥漫大B细胞淋巴瘤患者的临床资料.根据治疗方法不同,将患者分为对照组(化疗治疗,n=39)和观察组(利妥昔单抗辅助化疗治疗,n=42).分析对比两组近期疗效、血清学指标,预后情况以及不良反应.结果:观察组近期疗效(78.57％)明显高于对照组(56.41％)(P<0.05).与治疗前相比,两组治疗后的CRP、TNF-α、CA125水平均显著下降,且观察组比对照组降低得更为显著(P<0.05).与治疗前相比,治疗后两组预后指数评分均显著下降(P<0.05),且观察组比对照组降低得更为显著(P<0.05).治疗后,两组的不良反应发生率无明显差异(P>0.05).结论:在治疗弥漫大B细胞淋巴瘤患者中,采用利妥昔单抗辅助化疗的治疗效果明显,有效改善患者的临床症状及预后情况,且安全性较好.     

认知行为治疗联合药物治疗强迫症疗效的meta分析

目的:通过对随机对照试验的数据进行meta分析,比较药物联合认知行为治疗(CBT)与单纯药物或CBT治疗对强迫症的疗效,为临床实践提供选择依据.方法:检索PubMed、Embase和Central数据库,收集比较药物联合CBT与单纯药物或CBT治疗强迫症疗效的随机对照试验,选取联合治疗组与单纯治疗组的耶鲁-布朗强迫量表测量数据并采用均差作为效应量,应用RevMan5软件进行meta分析.结果:共纳入7项符合标准的研究,合计样本量468人.排除可能引起异质性的1组数据后,3组数据比较了药物联合CBT与单纯药物治疗的疗效且无异质性(Q=0.48,P＞0.1),结果显示联合治疗组对强迫症状的改善优于单纯药物组(MD =6.46,Z=5.03,P≤0.05);7组数据比较了药物治疗联合CBT与单纯CBT的疗效且无异质性(Q=9.08,P＞0.1),结果显示联合治疗组与单纯CBT组对强迫症状的改善没有差别(MD =0.87,Z=1.22,P＞0.05).结论:鉴于目前结果,推测对于强迫症状的改善,药物治疗联合CBT优于单纯药物治疗而与单纯CBT相当,但仍需进一步研究证实.     

A novel combination chemotherapy integrating with intratumoral chemotherapy

The effects of conventional systemic chemotherapy are very modest, while the side-effects are very severe. Thus, intratumoral chemotherapy emerges as a new adjuvant treatment modality due to its several potential advantages. However, most researchers currently select only single cytotoxic drug as model drug at present studies, while ignore the combination administration. So, we hypothesize whether we can integrate the advantages of combination chemotherapy and intratumoral chemotherapy to achieve good antitumour effectiveness and minimal systemic side-effects and resistance. We propose that several drugs based on the cancer cell cycle are reserved in the microsphere-gel. Firstly, cell cycle specific agents (CCSA) are encapsulated into microspheres, then cell cycle non-specific agents and CCSA-loaded microspheres are dispersed into pre-gel solution. Eventually the goal of sequential, intermittent and combination chemotherapy is achieved. Therefore, the hypothesis has the potential application to treat cancer owing to its advantages of targeting effect, high efficiency, low side-effects and resistance, convenience.     

Coping with chemotherapy for breast cancer

Relations among coping, physical symptoms, and affect were investigated in 43 women undergoing adjuvant chemotherapy for breast cancer. Patients were assessed at the same point in their treatment so that the time for which coping was reported would be equivalent across individuals. Patients were asked how they coped specifically with chemotherapy, rather than how they coped with cancer in general, to make the domain specific. Positive and negative affect were assessed separately, using a scale free of somatic content. Relations between coping and affect were consistent with prior studies that have employed a general approach to assessing coping. Coping correlates of positive and negative mood differed. When the relations between physical symptoms and affect were examined, physical symptoms were related to negative affect but not to positive affect. Findings are discussed in terms of their implications for coping with cancer as well as their implications for the general coping literature.     

Gynecomastia with marked cellular atypia associated with chemotherapy

Gynecomastia is a common benign male breast disease, which may exhibit mild cellular atypia in cytology specimens. However, marked cytologic atypia can be seen in gynecomastia superimposed by chemotherapy. The case described in this report demonstrated severe cytologic atypia of gynecomastia mimicking carcinoma in a patient treated with chemotherapy for acute leukemia. A distinct cytologic feature helpful in avoiding the diagnostic error is described, namely, atypical cells admixed with bland ductal cells and appearing at a different plane. The importance of applying strict diagnostic criteria in breast cytology and clinical correlation is also emphasized.     

Myelomatous effusion with poor response to chemotherapy

While pleural effusion in multiple myeloma is relatively infrequent, myelomatous pleural effusion is extremely rare. We experienced a 61-year-old woman with IgD-lambda multiple myeloma and pleural effusion. The diagnosis was made originally by pleural biopsy, pleural fluid cytology and immunoelectropheresis of pleural fluid. Transient improvement of the pleural effusion was observed after administration of combination chemotherapy of vincristine, melphalan, cyclophosphamide, prednisone (VMCP)/vincristine, cyclophosphamide, adriamycin, prednisone (VCAP). Two months later, myelomatous pleural effusion recurred and no response to salvage therapy was observed. We reviewed the clinical feature of this case and literature concerning myelomatous pleural effusion.     

Evolution of chemotherapy with platinum compounds.

Cancer is a major disease entity and cause of death in the human population. The discovery of cisplatin has revolutionized the chemotherapy of human cancer. The full therapeutic potential of cisplatin has not been realized due to the serious side effects and emergence of cisplatin-resistant tumor cells associated with its usage. Protective methods such as extensive hydration, improved schedules of administration, alternate routes of administration, and use of protective agents against specific side effects have allowed the use of higher doses of cisplatin against cisplatin-resistant tumors and has extended the list of tumor systems responsive to cisplatin chemotherapy. Incorporation of cisplatin into a number of cisplatin-based anti-cancer drug combinations has enhanced its effectiveness and allowed the use of lower doses of cisplatin, thus reducing its toxic side effects. Finally, the availability of cisplatin analogues, such as carboplatin and others with reduced toxicity, but increased effectiveness against cisplatin-resistant tumors, has expanded the potential scope and therapeutic promise of the platinum anti-cancer agents. The evolution of chemotherapy with the platinum antitumor compounds is ongoing.